Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $14.57M rose 60.3% year over year, ahead of the +34.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +31.8% a year.
Context
- Selling, general & admin amounted to 105.1% of revenue in FY2025, up 17.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $263.88M (+462.5%) for the fiscal year ending Dec 2026, a step up from the +13.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.57M-4.4% QoQ
- Last fiscal yearDec 2025
- $46.91M+13.1% YoY
- LTMMar 2026
- $53.08M+34.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 46.91M USD
- Year-over-year change
- +13.1%
- 4-year CAGR
- +39.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.91M | +13.1% |
| FY2024 | 2024-12-31 | 41.48M | +26.8% |
| FY2023 | 2023-12-31 | 32.71M | +59.5% |
| FY2022 | 2022-12-31 | 20.51M | +67.5% |
| FY2021 | 2021-12-31 | 12.24M | — |
Selling, General & Admin vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +34.4% is the 3rd highest of 8, against a peer median of +1.0%.
- Selling, general & admin amounts to 103.7% of revenue for FRX.TO, versus a peer median of 37.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$122.93M CAD | +1.0% | -25.6% | 39.5% | |
| LTM Mar 2026 | $113.29M USD | -17.3% | -15.6% | 37.1% | |
| LTM Mar 2026 | CA$92.99M CAD | +36.2% | — | 33.9% | |
| LTM Mar 2026 | $84.46M USD | -22.8% | -10.9% | 32.3% | |
| LTM Mar 2026 | $53.08M USD | +34.4% | +31.8% | 103.7% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $30.43M USD | +14.7% | +22.1% | 162.2% |
| LTM Mar 2026 | $17.9M USD | +115.0% | +43.3% | — | |
| LTM Apr 2026 | CA$1.67M CAD | -34.6% | +45.7% | — | |
| Peer median (excluding FRX.TO) | — | +1.0% | +5.6% | 37.1% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 254.38K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.04M | 32.76M | 41.79M | 47.22M |
| Depreciation & Amortization | 17.22M | 149K | 287K | 800K | 103K |
| EBITDA | (17.19M) | (22.74M) | (12.65M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1481.2% | -59.5% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.59M) | (12.77M) | 2.57M | (6.35M) |
| Operating Margin | — | -1471.6% | -60.1% | 5.4% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.68M | 800.78K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.18M |
| Other Income / Expenses | (123K) | (1.13M) | (3.27M) | (2.64M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 110K | 147K | 0 | 365K | 106K |
| Net Income | (17.46M) | (23.86M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1554.5% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| EPS (Diluted) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| Weighted Avg Shares | 25.89M | 26.28M | 26.57M | 21.8M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.3M | 28.58M |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.